Aptose Q1 net loss $5.5M, cash only until end-May 2025; cites need for financing

Aptose Biosciences Inc.

2025-Q1 EPS reported -$2.61

Net loss of $5.5M for Q1 2025 vs. $9.6M a year ago; EPS loss $2.61.
Cash and restricted cash $4.7M; company expects runway only through May 2025.
TUSCANY trial: all six patients on 40 or 80 mg TUS+VEN+AZA achieved complete remissions.
Common shares delisted from Nasdaq effective April 2, 2025 due to equity deficiency.
Management pursuing financing and cost cuts to extend cash runway beyond May 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.